Research programme: glioma diagnostics and therapeutics - Arch Biopartners

Drug Profile

Research programme: glioma diagnostics and therapeutics - Arch Biopartners

Alternative Names: MetaMx

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator Arch Biopartners
  • Developer Arch Biopartners; d3 Medicine
  • Class Peptides
  • Mechanism of Action Diagnostic imaging enhancers; Magnetic resonance imaging enhancers; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioma

Most Recent Events

  • 08 Sep 2016 Preclinical development for Glioma (Treatment and Diagnosis) is underway in Canada (Arch Biopartners website, September 2016)
  • 07 Sep 2016 d3 Medicine has been acquired by Certara
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Glioma in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top